Novo Nordisk Wegovy Strategy +2.9% Rally After 70% Slide
Can the aggressive Novo Nordisk Wegovy Strategy subscription push really reverse a 70% stock slide and close the gap to Eli Lilly? Maik Kemper Editor…
AbbVie Dermatology Data Boom at AAD 2026 Shocks Investors
Can AbbVie’s latest dermatology data at AAD 2026 really secure its post-Humira growth story in immunology? Maik Kemper Editor in Chief Our robust evidence across…
Hims & Hers GLP-1 partnership sparks new weight-loss boom
Can the Hims & Hers GLP-1 partnership with Novo Nordisk turn telehealth weight loss into the company’s next major growth engine? Maik Kemper Editor in…
Merck Terns Acquisition $6.7B Surge as Keytruda Cliff Nears
Can the Merck Terns Acquisition really plug the looming Keytruda revenue gap or is $6.7 billion just a high-risk oncology bet? Maik Kemper Editor in…
Eli Lilly GLP-1 Strategy Boom and Revenue Shock
Can Eli Lilly’s GLP-1 boom keep powering the stock as regulation, lawsuits and ETF concentration risks close in? Maik Kemper Editor in Chief Conclusion The…
Pfizer Lyme vaccine 70% efficacy Shock as PFE slips
Can the Pfizer Lyme vaccine’s >70% efficacy data revive sentiment around PFE just as investors write off its post-COVID growth story? Maik Kemper Editor in…